IN2014MN02101A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02101A IN2014MN02101A IN2101MUN2014A IN2014MN02101A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A IN 2101MUN2014 A IN2101MUN2014 A IN 2101MUN2014A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A
- Authority
- IN
- India
- Prior art keywords
- heart failure
- present
- chronic heart
- stable chronic
- procalcitonin
- Prior art date
Links
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 2
- 108010048233 Procalcitonin Proteins 0.000 abstract 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12163921 | 2012-04-12 | ||
| PCT/EP2013/057626 WO2013153177A1 (en) | 2012-04-12 | 2013-04-11 | Prognosis of adverse events in patients with suspected chronic heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02101A true IN2014MN02101A (en) | 2015-08-28 |
Family
ID=48050768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2101MUN2014 IN2014MN02101A (en) | 2012-04-12 | 2013-04-11 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9488659B2 (en) |
| EP (1) | EP2836841B1 (en) |
| JP (1) | JP5945063B2 (en) |
| CN (1) | CN104303061B (en) |
| BR (1) | BR112014025189B1 (en) |
| HK (1) | HK1203611A1 (en) |
| IN (1) | IN2014MN02101A (en) |
| RU (1) | RU2672561C2 (en) |
| WO (1) | WO2013153177A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836841B1 (en) * | 2012-04-12 | 2022-01-05 | B.R.A.H.M.S GmbH | Prognosis of adverse events in patients with suspected chronic heart failure |
| EP2990800A1 (en) * | 2014-08-29 | 2016-03-02 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Neprilysin as heartfailure (HF) prognostic marker |
| US11143659B2 (en) | 2015-01-27 | 2021-10-12 | Arterez, Inc. | Biomarkers of vascular disease |
| US10368774B2 (en) * | 2015-07-30 | 2019-08-06 | Medtronic, Inc. | Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event |
| CN105929152B (en) * | 2016-07-15 | 2018-06-26 | 安徽国科生物科技有限公司 | A kind of intelligent detecting instrument for Procalcitonin detection |
| SG11201906939XA (en) * | 2017-02-06 | 2019-08-27 | Resiliun B V | Interaction between c-peptides and elastin receptor, a model for understanding vascular disease |
| CN108931658A (en) * | 2018-04-16 | 2018-12-04 | 上海交通大学医学院附属瑞金医院 | For diagnosis of heart failure complication and the serum markers of prognosis evaluation |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| RU2766252C1 (en) * | 2021-04-13 | 2022-02-10 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Method for predicting risk of death in patients with chronic heart failure using endogenous blood serum erythropoietin |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| DE19847690A1 (en) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Diagnosing sepsis and severe infections, useful for assessing severity and progress of treatment, by measuring content of peptide prohormone or their derived fragments |
| DE102006046996A1 (en) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnosis process for respiratory infections involves using procalcitonin as marker for assessing patient risk level |
| CN101029897A (en) * | 2007-02-09 | 2007-09-05 | 深圳市新产业生物医学工程有限公司 | Calcitonin reagent unit and its testing method |
| DE102007009751A1 (en) * | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Diagnostic immunoassay for procalcitonin in a biological sample from a patient comprises selectively determining full-length procalcitonin 1-116 |
| CN110346577A (en) * | 2007-08-03 | 2019-10-18 | B.R.A.H.M.S 有限公司 | Application of the Procalcitonin (PCT) in the risk stratification and prognosis of patient for suffering from primary uninfection |
| EP2101178A1 (en) | 2008-03-12 | 2009-09-16 | BRAHMS Aktiengesellschaft | Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes |
| RU2357250C1 (en) * | 2007-12-10 | 2009-05-27 | Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" | Chronic cardial insufficiency course prediction method |
| DK2419741T3 (en) | 2009-04-14 | 2019-11-04 | Brahms Gmbh | RISK ASSESSMENT OF ANTIBIOTIC TREATMENT OF PATIENTS SUFFERED BY PRIMARY NON-INFECTIOUS DISEASE, IN DETERMINING THE PROCALCITONIN LEVEL |
| EP2284540A1 (en) * | 2009-07-31 | 2011-02-16 | BIOCRATES Life Sciences AG | Method of diagnosing organ failure |
| CN201886025U (en) * | 2010-12-10 | 2011-06-29 | 四川迈克生物科技股份有限公司 | Immunochromatography strip for rapidly and quantitatively detecting procalcitonin |
| EP2836841B1 (en) * | 2012-04-12 | 2022-01-05 | B.R.A.H.M.S GmbH | Prognosis of adverse events in patients with suspected chronic heart failure |
-
2013
- 2013-04-11 EP EP13714980.3A patent/EP2836841B1/en active Active
- 2013-04-11 CN CN201380019816.2A patent/CN104303061B/en active Active
- 2013-04-11 JP JP2015504958A patent/JP5945063B2/en active Active
- 2013-04-11 RU RU2014145259A patent/RU2672561C2/en active
- 2013-04-11 WO PCT/EP2013/057626 patent/WO2013153177A1/en active Application Filing
- 2013-04-11 BR BR112014025189A patent/BR112014025189B1/en active IP Right Grant
- 2013-04-11 IN IN2101MUN2014 patent/IN2014MN02101A/en unknown
- 2013-04-11 US US14/391,953 patent/US9488659B2/en active Active
-
2015
- 2015-04-21 HK HK15103849.0A patent/HK1203611A1/en unknown
-
2016
- 2016-07-15 US US15/211,802 patent/US9753039B2/en active Active
-
2017
- 2017-09-01 US US15/693,880 patent/US20170370940A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9488659B2 (en) | 2016-11-08 |
| RU2672561C2 (en) | 2018-11-16 |
| JP2015515630A (en) | 2015-05-28 |
| JP5945063B2 (en) | 2016-07-05 |
| BR112014025189A2 (en) | 2017-07-11 |
| US20150079696A1 (en) | 2015-03-19 |
| EP2836841B1 (en) | 2022-01-05 |
| US20160320411A1 (en) | 2016-11-03 |
| HK1203611A1 (en) | 2015-10-30 |
| WO2013153177A1 (en) | 2013-10-17 |
| RU2014145259A (en) | 2016-06-10 |
| CN104303061B (en) | 2017-05-31 |
| EP2836841A1 (en) | 2015-02-18 |
| BR112014025189B1 (en) | 2020-04-07 |
| US20170370940A1 (en) | 2017-12-28 |
| CN104303061A (en) | 2015-01-21 |
| US9753039B2 (en) | 2017-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02101A (en) | ||
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| MX367046B (en) | Pathway specific markers for diagnosing irritable bowel syndrome. | |
| EA201400119A1 (en) | PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR APPLICATION | |
| MX2016002165A (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels. | |
| NZ707139A (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| UA116196C2 (en) | Synthetic apelin mimetics for the treatment of heart failure | |
| MX2014000363A (en) | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses. | |
| IN2015DN01767A (en) | ||
| MX2013001906A (en) | Methods of reducing blood lactate concentration. | |
| EA201500997A1 (en) | THERAPEUTIC APPLICATIONS OF EMAGOGLIFLOSINE | |
| EA201490883A1 (en) | APPLICATION OF ANTIBODIES TO α-SINUCULINE FOR DIAGNOSTIC OF THE INCREASED LEVEL OF α-SINUCLEIN IN THE BRAIN | |
| BR112012016894A2 (en) | lactobacilli with antioxidant action. | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| MX2016001195A (en) | Methods for improving asthma symptoms using benralizumab. | |
| PH12014501176A1 (en) | Anticoagulant reversal agents | |
| TR201907907T4 (en) | Methods of increasing the forced expiratory volume in asthmatic patients using benralizumab. | |
| WO2012160551A3 (en) | Methods and compositions for determining heart failure or a risk of heart failure | |
| AU2012313353A8 (en) | Screening method | |
| IN2014DN08312A (en) | ||
| EA201270315A1 (en) | NEW FORMS OF POLYCYCLIC CONNECTION | |
| MX364626B (en) | Mimetic peptides. | |
| EA201391772A1 (en) | METHOD OF DIAGNOSTIC RHEUMATOID ARTHRITIS | |
| MX364003B (en) | Treatment of insulin resistance through inhibitors of transcription factor tsc22d4. | |
| TR201906948T4 (en) | Rehospitalization biomarker after heart failure. |